End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
82.24 CNY | +1.34% |
|
+2.30% | +12.09% |
Jan. 20 | Xiamen Amoytop Biotech's Electronic Pen Injector Gets Registration Certificate from China's Fujian Province | MT |
Jan. 06 | Xiamen Amoytop Biotech Gets Clinical Trial Approval for Peijin Drug | MT |
Capitalization | 33.46B 4.61B 4.39B 4.14B 3.66B 6.54B 400B 7.25B 49.31B 18.27B 167B 17.29B 16.94B 701B | P/E ratio 2024 * |
42.4x | P/E ratio 2025 * | 30.6x |
---|---|---|---|---|---|
Enterprise value | 33.46B 4.61B 4.39B 4.14B 3.66B 6.54B 400B 7.25B 49.31B 18.27B 167B 17.29B 16.94B 701B | EV / Sales 2024 * |
11.9x | EV / Sales 2025 * | 9.03x |
Free-Float |
31.6% | Yield 2024 * |
-
| Yield 2025 * | 0.43% |
1 day | +1.34% | ||
1 week | +2.30% | ||
Current month | +1.68% | ||
1 month | +14.80% | ||
3 months | +9.04% | ||
6 months | +64.15% | ||
Current year | +12.09% |







Director | Title | Age | Since |
---|---|---|---|
Li Sun
CEO | Chief Executive Officer | 59 | 2013-04-30 |
Yi Ling Yang
DFI | Director of Finance/CFO | 50 | 2021-09-09 |
Li Ping Lai
PRN | Corporate Officer/Principal | 54 | 1996-08-06 |
Manager | Title | Age | Since |
---|---|---|---|
Chun Lan
CHM | Chairman | 59 | 2014-07-31 |
Li Sun
CHM | Chairman | 59 | 2020-08-30 |
Ying Yang
BRD | Director/Board Member | 62 | 2015-08-05 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+1.34% | +2.30% | +33.38% | +227.52% | 4.61B | ||
+1.14% | -4.80% | -8.31% | +5.48% | 79.12B | ||
+1.90% | +17.90% | +40.69% | +56.37% | 58.36B | ||
-3.58% | -4.65% | +91.85% | +112.44% | 35.96B | ||
-0.81% | -2.84% | -37.79% | -35.86% | 20.1B | ||
-1.85% | -5.48% | +327.83% | +820.50% | 14.59B | ||
+0.59% | -5.00% | +21.64% | +6.66% | 13.63B | ||
-0.19% | +0.64% | +77.55% | +141.17% | 13.58B | ||
+0.67% | +1.44% | -24.60% | -27.95% | 12.36B | ||
+4.31% | +0.99% | +9.19% | -32.53% | 11.95B | ||
Average | +0.35% | -1.43% | +53.14% | +127.38% | 26.43B | |
Weighted average by Cap. | +0.38% | -2.25% | +39.17% | +80.75% |
2024 * | 2025 * | |
---|---|---|
Net sales | 2.8B 387M 368M 347M 307M 548M 33.49B 608M 4.13B 1.53B 14B 1.45B 1.42B 58.79B | 3.71B 511M 487M 459M 405M 724M 44.27B 804M 5.46B 2.02B 18.51B 1.92B 1.88B 77.72B |
Net income | 819M 113M 107M 101M 89.53M 160M 9.78B 177M 1.21B 447M 4.09B 423M 415M 17.17B | 1.1B 151M 144M 136M 120M 214M 13.08B 237M 1.61B 598M 5.47B 566M 555M 22.96B |
Net Debt | - | - |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 82.24 ¥ | +1.34% | 2,008,535 |
25-02-13 | 81.15 ¥ | -1.87% | 2,481,304 |
25-02-12 | 82.70 ¥ | +1.36% | 2,067,217 |
25-02-11 | 81.59 ¥ | +2.12% | 2,483,581 |
25-02-10 | 79.90 ¥ | -0.61% | 2,511,402 |
End-of-day quote Shanghai S.E., February 13, 2025
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 688278 Stock